Biotech IV Monitor

INCY — Incyte Corporation

$26.0B market cap · 6 upcoming readouts tracked

Clinical trial readout dates for Incyte Corporation, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts62 Phase 3
Market cap$26.0B
Cash & investments$3.28B~4 quarters at last loss rate
Recent 8-K filings2latest 2026-11-13

Recently completed

The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.

Phase 2 Axatilimab
Chronic Graft-versus-host-disease · NCT06388564
October 2026
Primary data collected
Phase 3 Ruxolitinib Cream
Hidradenitis Suppurativa · NCT06958211
October 2026
Primary data collected
Phase 3 Ruxolitinib
Atopic Dermatitis · NCT06832618
August 2026
Primary data collected
Phase 2 retifanlimab
Endometrial Cancer · NCT04463771
May 2026
Primary data collected

Upcoming readouts

Phase 3 Povorcitinib
Hidradenitis Suppurativa (HS) · NCT06212999
December 2026
Ongoing
Phase 1/2 INCA034176
Chronic Graft-versus-host-disease · NCT06843408
January 2027
Ongoing
Phase 2 INCB123667
Ovarian Cancer · NCT07023627
April 2027
Recruiting
Phase 3 Ruxolitinib Cream
NonSegmental Vitiligo · NCT06804811
April 2027
Recruiting
Phase 2 INCB000928
Fibrodysplasia Ossificans Progressiva (FOP) · NCT05090891
July 2027
Recruiting
Phase 2 Tafasitamab
Hematologic Malignancies · NCT06465433
August 2027
Recruiting

Target dates already passed

These dates have elapsed; the company may have reported, or guidance may have shifted.

Phase 2 Parsaclisib
B-Cell Malignancies · NCT04509700
November 2026
Ongoing
Phase 2 povorcitinib
Moderate to Severe Asthma · NCT05851443
November 2026
Ongoing

Cash position

Incyte Corporation reported $3.28B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-29). Its net loss for that quarter was $785M; at that rate the cash would last about 4 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Other Events — often topline trial data2026-11-13
8-K Results of Operations — earnings, may carry pipeline updates2026-10-29

Companies working on similar indications

Discussion

No messages yet. If you follow INCY, you can start the conversation.
Track INCY in real time
See live implied volatility for INCY and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on INCY
Contact — questions or corrections about INCY: dukeupt@gmail.com